We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. (2019-101826)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04896320
Recruitment Status : Recruiting
First Posted : May 21, 2021
Last Update Posted : January 31, 2022
Sponsor:
Collaborator:
Seagen Inc.
Information provided by (Responsible Party):
Providence Health & Services

Brief Summary:
This is an open label study of tucatinib in combination with either vinorelbine or gemcitabine and trastuzumab in patients with metastatic HER2+ breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Stage IV Drug: Tucatinib Phase 1 Phase 2

Detailed Description:

This phase I/II study will assess the recommended dosing of tucatinib in combination with trastuzumab and either vinorelbine or gemcitabine in patients with advanced, HER2+ breast cancer. The study will be conducted as a parallel cohort study looking at optimal dose and safety and efficacy.

Arm 1 Gemcitabine + Tucatinib + Trastuzumab: Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.

Arm 2 Vinorelbine + Tucatinib + Trastuzumab: Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each 2 cycle.

Note: Cycle length is 21 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of Tucatinib With Chemotherapy and Trastuzumab in Patients With Previously Treated, Advanced Her-2-Neu Overexpressing Breast Cancer.
Actual Study Start Date : December 15, 2021
Estimated Primary Completion Date : December 2030
Estimated Study Completion Date : December 2032

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Gemcitabine + Tucatinib + Trastuzumab
Gemcitabine (1000 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
Drug: Tucatinib
Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).

Experimental: Vinorelbine + Tucatinib + Trastuzumab
Vinorelbine (25 mg/m2) will be administered intravenously on Days 1 and 8 of each 21-day cycle. The investigational study drug (tucatinib) will be administered as 300mg by mouth taken twice a day of every day in each cycle. Trastuzumab will be administered per package insert on Day 1 of each cycle.
Drug: Tucatinib
Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).




Primary Outcome Measures :
  1. To determine the maximum tolerated dose and recommended dosing of tucatinib to be given in combination with either vinorelbine or gemcitabine and trastuzumab. [ Time Frame: Cycle 1 Day 1 (each cycle is 21 days) to 30 Day Safety Follow-Up (after treatment), approximately 14 weeks ]

Secondary Outcome Measures :
  1. Study Treatment-Related Adverse Events [ Time Frame: Cycle 1 Day 1 (each cycle is 21 days) to 30 Day Safety Follow-Up, approximately 14 weeks ]
    Number of participants given tucatinib in combination with vinorelbine or gemcitabine with trastuzumab with treatment-related adverse events as assessed by CTCAE v5.0 with Her-2-neu overexpressing metastatic breast cancer.

  2. Overall Response Rate [ Time Frame: Up to 5 Years ]
    Number of patients who have a partial or complete response to treatment per RECIST 1.1.

  3. Progression Free Survival [ Time Frame: Up to 5 Years ]
    Length of time from start of study treatment to disease progression or death from any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >18, with metastatic breast cancer, documented Her2+ by FISH/Dual-ISH, and/or IHC 3+ staining, local determination of Her2+ allowed
  2. Progressive disease with history of prior treatment with trastuzumab and capecitabine for metastatic disease (unless deemed intolerable or ineligible for capecitabine by the investigator).
  3. Prior treatment with T-DM1 in any setting unless deemed intolerable or ineligible for T-DM1 by the investigator.
  4. Target or non-target lesions per RECIST 1.1.
  5. ECOG 0 or 1.
  6. In the opinion of the investigator, life expectancy >6 months.
  7. LVEF > 50% by ECHO or MUGA within 4 weeks prior to first study treatment.
  8. Cr Clearance > 50mL/min per institutional guidelines.
  9. Negative serum pregnancy test for women of child bearing potential within 14 days of first study treatment and must agree to use effective contraception through 30 days after last treatment.

    For subjects who can father children:

    • Must agree not to donate sperm starting at time of informed consent and continuing throughout the study period and for at least 30 days after the final study drug administration.
    • If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use a barrier method of birth control starting at time of informed consent and continuing throughout the study and for at least 30 days after the final dose of study drug administration.
    • If sexually active with a person who is pregnant or breastfeeding, must consistently use a barrier method of birth control starting at time of informed consent and continuing throughout the study and for at least 30 days after the final dose of study drug administration.
  10. Willing and able to provide written Informed consent.
  11. All toxicities related to prior cancer therapies must have resolved to < grade 1, with following exceptions: alopecia, neuropathy, which must have resolved to <Grade 2; congestive heart failure which must have been <grade 1 in severity at the time of occurrence and resolved completely.
  12. Adequate hematologic and hepatic function as defined by:

    • Hemoglobin >9g/dL
    • Absolute neutrophil count (ANC)>1000 cells/uL
    • Platelets >100,000/uL
    • Total bilirubin < 1.5 X upper limit of normal (ULN), except for subjects with known Gilbert's disease, who may enroll if the conjugated bilirubin is < 1.5 X ULN
    • Transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase [AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase [ALT/SGPT]) ≤ 2.5 X ULN (≤ 5 X ULN if liver metastases are present)
  13. CNS Inclusion - Based on screening contrast brain MRI, patients must have one of the following:

    • No evidence of brain metastases
    • Untreated brain metastases not needing immediate local therapy. For patients with untreated CNS lesions > 2.0 cm on screening contrast brain MRI, discussion with and approval from the medical monitor is required prior to enrollment
    • Previously treated brain metastases

A. Brain metastases previously treated with local therapy may either be stable since treatment or may have progressed since prior local CNS therapy, provided that there is no clinical indication for immediate re-treatment with local therapy in the opinion of the investigator.

B. Patients treated with CNS local therapy for newly identified lesions found on contrast brain MRI performed during screening for this study may be eligible to enroll if all of the following criteria are met:

i. Time since WBRT is ≥ 21 days prior to first dose of treatment, time since SRS is ≥ 7 days prior to first dose of treatment, or time since surgical resection is ≥ 28 days ii. Other sites of disease assessable by RECIST 1.1 are present C. Relevant records of any CNS treatment must be available to allow for classification of target and non-target lesions

Exclusion Criteria:

  1. Having previous treatment with vinorelbine and gemcitabine for metastatic disease.
  2. History of allergic reactions to trastuzumab except for grade 1/2 infusion reactions.
  3. History of allergic reactions to tucatinib.
  4. Any systemic anti-cancer therapy <14 days of first study treatment, including any experimental agents.
  5. Clinically significant cardiopulmonary disease including ventricular arrhythmia requiring therapy

    • Uncontrolled hypertension (defined as persistent systolic blood pressure > 150mmHG and/or diastolic blood pressure >100mm Hg on antihypertensive medication) or any history of symptomatic CHF
  6. Known history of HIV, Hep B/C or known chronic liver disease.
  7. Known MI or unstable angina in last 6 months prior to first study treatment
  8. Inability to swallow pills or significant GI disease, in the opinion of the Investigator that would preclude oral absorption of the medication.
  9. Are pregnant, breastfeeding, or planning pregnancy.
  10. CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:

    A. Any untreated brain lesions > 2.0 cm in size, unless discussed with medical monitor and approval for enrollment is given.

    B. Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent). However, patients on a chronic stable dose of ≤ 2 mg total daily of dexamethasone (or equivalent) may be eligible with discussion and approval by the medical monitor.

    C. Any brain lesion thought to require immediate local therapy, including (but not limited to) a lesion in an anatomic site where increase in size or possible treatment-related edema may pose risk to patient (e.g. brain stem lesions). Patients who undergo local treatment for such lesions identified by screening contrast brain MRI may still be eligible for the study based on criteria described under CNS inclusion criteria.

    D. Known or suspected LMD as documented by the investigator. E. Have poorly controlled (> 7days) generalized or complex partial seizures, or manifest neurologic progression due to brain metastases notwithstanding CNS-directed therapy

  11. Use of a strong CYP3A4 or CYP2C8 inhibitor within ≤14days, or use of a strong CYP3A4 or CYP2C8 inducer within ≤5 days prior to the first study treatment. CYP3A4 or CYP2C8 inducers and inhibitors are also prohibited as concomitant medications within ≤14 days of initiating Tucatinib treatment. . Use of sensitive CYP3A substrates should be avoided two weeks before enrollment and during study treatment. See Appendices C, D, E for references. (See Section 7.6 for additional prohibited concomitant medications)
  12. Prior radiation therapy less than 7 days from start of treatment.
  13. Other medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04896320


Contacts
Layout table for location contacts
Contact: Nikki Moxon, RN 503-215-2619 nicole.moxon@providence.org

Locations
Layout table for location information
United States, Oregon
Providence Cancer Institute - Clackamas Clinic Recruiting
Clackamas, Oregon, United States, 97015
Contact: Nikki Moxon, RN    503-215-2619    nicole.moxon@providence.org   
Principal Investigator: Alison Conlin, MD         
Sub-Investigator: Janet Ruzich, DO         
Sub-Investigator: Shane Rogosin, MD         
Providence Newberg Medical Center Recruiting
Newberg, Oregon, United States, 97132
Contact: Nikki C Moxon, RN    503-215-2619    nicole.moxon@providence.org   
Principal Investigator: Alison Conlin, MD         
Sub-Investigator: Kelly Perlewitz, MD         
Portland Providence Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Nikki Moxon, RN    503-215-2619    nicole.moxon@providence.org   
Principal Investigator: Alison Conlin, MD         
Sub-Investigator: Janet Ruzich, DO         
Sub-Investigator: Shane Rogosin, MD         
Sub-Investigator: David Page, MD         
Sub-Investigator: Evelyn Brosnan, MD         
Sub-Investigator: Sasha Stanton, MD         
Providence St. Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Nikki Moxon, RN    503-215-2619    nicole.moxon@providence.org   
Principal Investigator: Alison Conlin, MD         
Sub-Investigator: Christine Johnson, MD         
Sub-Investigator: David Page, MD         
Sub-Investigator: Sasha Stanton, MD         
Sponsors and Collaborators
Providence Health & Services
Seagen Inc.
Investigators
Layout table for investigator information
Principal Investigator: Alison Conlin, MD Providence Health & Services
Layout table for additonal information
Responsible Party: Providence Health & Services
ClinicalTrials.gov Identifier: NCT04896320    
Other Study ID Numbers: 2021000247
First Posted: May 21, 2021    Key Record Dates
Last Update Posted: January 31, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Providence Health & Services:
Metastatic
Her2+
Trastuzumab
Tucatinib
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Tucatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action